CAL
ESPR

Capital Advisors Ltd’s Esperion Therapeutics ESPR Stock Holding History

Capital Advisors Ltd’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-467
Closed -$3K – 1293
2022
Q4 		$3K Hold
467
– – ﹤0.01% 760
2022
Q3 		$3K Hold
467
– – ﹤0.01% 736
2022
Q2 		$3K Buy
467
+139
+42% +$788 ﹤0.01% 618
2022
Q1 		$2K Buy
+328
New +$1.41K ﹤0.01% 633

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Capital Advisors Ltd's ESPR Position: Q1 2023 in Review

Capital Advisors Ltd sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 467 shares — an estimated $3K sold.

Capital Advisors Ltd first reported a position in ESPR in Q1 2022 and held it in 4 quarters. The position peaked at $3K in Q4 2022. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Capital Advisors Ltd reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 467 Esperion Therapeutics shares in Q1 2023, an estimated $3K.
  • Capital Advisors Ltd first reported a position in Esperion Therapeutics in Q1 2022 and held it in 4 quarters.
  • Capital Advisors Ltd's Esperion Therapeutics position peaked at $3K in Q4 2022.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.